These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
333 related articles for article (PubMed ID: 33734289)
1. Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial. Zenke Y; Tsuboi M; Chiba Y; Tsujino K; Satouchi M; Sawa K; Shimizu J; Daga H; Fujimoto D; Mori M; Aoki T; Sawa T; Omori S; Saka H; Iwamoto Y; Okuno M; Hirashima T; Kashiwabara K; Tachihara M; Ymamoto N; Nakagawa K JAMA Oncol; 2021 Jun; 7(6):904-909. PubMed ID: 33734289 [TBL] [Abstract][Full Text] [Related]
2. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. Yamamoto N; Nakagawa K; Nishimura Y; Tsujino K; Satouchi M; Kudo S; Hida T; Kawahara M; Takeda K; Katakami N; Sawa T; Yokota S; Seto T; Imamura F; Saka H; Iwamoto Y; Semba H; Chiba Y; Uejima H; Fukuoka M J Clin Oncol; 2010 Aug; 28(23):3739-45. PubMed ID: 20625120 [TBL] [Abstract][Full Text] [Related]
3. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer. Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799 [TBL] [Abstract][Full Text] [Related]
5. Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial. Ross HJ; Kozono D; Wang XF; Urbanic JJ; Williams TM; Nelson GD; Carbone DP; Chung D; Robb R; Byun WY; Talabere T; DuFrane C; Bara I; Schulze K; Brockman M; Gao J; Vokes EE; Stinchcombe TE JAMA Oncol; 2024 Sep; 10(9):1212-1219. PubMed ID: 39052256 [TBL] [Abstract][Full Text] [Related]
6. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342 [TBL] [Abstract][Full Text] [Related]
7. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739 [TBL] [Abstract][Full Text] [Related]
8. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial. Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review. Steuer CE; Behera M; Ernani V; Higgins KA; Saba NF; Shin DM; Pakkala S; Pillai RN; Owonikoko TK; Curran WJ; Belani CP; Khuri FR; Ramalingam SS JAMA Oncol; 2017 Aug; 3(8):1120-1129. PubMed ID: 27978552 [TBL] [Abstract][Full Text] [Related]
10. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Atagi S; Kawahara M; Yokoyama A; Okamoto H; Yamamoto N; Ohe Y; Sawa T; Ishikura S; Shibata T; Fukuda H; Saijo N; Tamura T; Lancet Oncol; 2012 Jul; 13(7):671-8. PubMed ID: 22622008 [TBL] [Abstract][Full Text] [Related]
11. Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer. Tsuchiya-Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I Oncologist; 2020 Jun; 25(6):475-e891. PubMed ID: 31649134 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer. Hasegawa T; Futamura Y; Horiba A; Yoshida T; Suzuki T; Kato T; Kaito D; Ohno Y; Iida T; Hayashi S; Sawa T J Radiat Res; 2016 Jan; 57(1):50-4. PubMed ID: 26442970 [TBL] [Abstract][Full Text] [Related]
14. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. Belani CP; Choy H; Bonomi P; Scott C; Travis P; Haluschak J; Curran WJ J Clin Oncol; 2005 Sep; 23(25):5883-91. PubMed ID: 16087941 [TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial. Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR; J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656 [TBL] [Abstract][Full Text] [Related]
17. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). Patel JD; Lee JW; Carbone DP; Wagner H; Shanker A; de Aquino MTP; Horn L; Johnson ML; Gerber DE; Liu JJ; Das MS; Al-Nsour MA; Dakhil CSR; Ramalingam S; Schiller JH Clin Lung Cancer; 2020 Nov; 21(6):520-526. PubMed ID: 32807654 [TBL] [Abstract][Full Text] [Related]
18. A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer. Carter DL; Garfield D; Hathorn J; Mundis R; Boehm KA; Ilegbodu D; Asmar L; Reynolds C Clin Lung Cancer; 2012 May; 13(3):205-13. PubMed ID: 22138037 [TBL] [Abstract][Full Text] [Related]
19. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. Lau D; Leigh B; Gandara D; Edelman M; Morgan R; Israel V; Lara P; Wilder R; Ryu J; Doroshow J J Clin Oncol; 2001 Jan; 19(2):442-7. PubMed ID: 11208837 [TBL] [Abstract][Full Text] [Related]
20. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. Chang JY; Verma V; Li M; Zhang W; Komaki R; Lu C; Allen PK; Liao Z; Welsh J; Lin SH; Gomez D; Jeter M; O'Reilly M; Zhu RX; Zhang X; Li H; Mohan R; Heymach JV; Vaporciyan AA; Hahn S; Cox JD JAMA Oncol; 2017 Aug; 3(8):e172032. PubMed ID: 28727865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]